Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The stock's fall snapped a two-day winning streak.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best humane stocks to invest in now. In recent years, the investment landscape has ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.96 which represents a slight increase of $1.12 or 1.22% from the prior close of $91.84. The stock opened at $92.06 and ...

Gilead Sciences, US Government Settle Patent Case ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health and Human ...